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a1-adrenoceptor antagonists can impact upon sexual function and have potential in the treatment of
erectile dysfunction. Human erectile tissue contains predominantly a1A-adrenoceptors, and here we
examined whether contractions of this tissue are mediated by the functional phenotype, the a1L-adre-
noceptor. Functional experiments using subtype selective agonists and antagonists, along with radio-
ligand ([3H]tamsulosin) binding assays, were used to determine the a1-adrenoceptor population. A61603,
a a1A-adrenoceptor agonist, was a full agonist with a potency 21-fold greater than that of noradrenaline.
The a1A- and a1D-adrenoceptor antagonist tamsulosin antagonized noradrenaline responses with high
afﬁnity (pKD ¼ 9.7 ± 0.3), whilst BMY7378 (100 nM) (a1D-adrenoceptor antagonist) failed to antagonize
responses. In contrast, relatively low afﬁnity estimates were obtained for both prazosin (pKD ¼ 8.2 ± 0.1)
and RS17053 (pKD ¼ 6.9 ± 0.2), antagonists which discriminate between the a1A- and a1L-adrenoceptors.
[3H]Tamsulosin bound with high afﬁnity to the receptors of human erectile tissue (pKD ¼ 10.3 ± 0.1) with
a receptor density of 28.1 ± 1.4 fmol mg1 protein. Prazosin displacement of [3H]tamsulosin binding
revealed a single homogenous population of binding sites with a relatively low afﬁnity for prazosin
(pKi ¼ 8.9). Taken together these data conﬁrm that the receptor mediating contraction in human erectile
tissue has the pharmacological properties of the a1L-adrenoceptor.
© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Penile erection (tumescence) is achieved when the erectile
tissue relaxes and becomes engorged with blood, caused by the
vasodilation of inﬂow arteries and compression of the outﬂow
veins. In contrast, activation of the sympathetic nervous system
causes contraction of the erectile tissue, mediated by postsynaptic
a1-adrenoceptors, and leads to ﬂaccidity and detumescence.1 Thus
a1-adrenoceptor antagonists have been investigated for their
potential therapeutic effect in the treatment of erectile dysfunction
and have been shown to impact upon sexual function. Intra-
cavernosal injection of a-adrenoceptor antagonists can relax erec-
tile smooth muscle and induce an erection,2,3 and positive effects ofch, Bond University, Robina,
).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).oral treatment of erectile dysfunction with a1-adrenoceptor
antagonists have been reported both experimentally4,5 and clini-
cally.6,7 These agents can also have adverse effects on erectile
dysfunction, with some of the newer generation a1-adrenoceptor
antagonists such as silodosin, used in the treatment of benign
prostatic hyperplasia, known to cause anejaculation.8e10 However,
the incidence of anejaculation is variable between a1-adrenoceptor
antagonists, and it remains unknown whether this effect is
mediated via genitourinary a1-adrenoceptors or centrally via
dopamine or serotonin receptors.11
Three a1-adrenoceptor subtypes (a1A, a1B and a1D) have been
classiﬁed via functional and molecular techniques.12 There is also
functional evidence for a fourth subtype, the a1L-adrenoceptor, also
known as the a1A/L-adrenoceptor, which represents a functional
phenotype of the a1A-adrenoceptor that is pharmacologically
distinct and has a low afﬁnity for prazosin.13e15 Human erectile
tissue expresses mRNA coding for all three cloned a1-adrenoceptor
subtypes, although it is the a1A-adrenoceptor subtype that pre-
dominates, with lower levels of a1D- and a1B-adrenoceptor mRNA.16nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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strated in receptor binding experiments, but there is disagreement
regardingwhich subtype predominates at the protein level. The a1A-
receptor has been reported as the major subtype,16 whilst Goepel
et al. (1999) reported both a1A- and a1B-adrenoceptors at the protein
level, with no evidence for the a1D-receptor.17 Functionally, a more
recent study concluded that the a1A-adrenoceptor was the main
subtype mediating contraction of the human cavernosum.18 How-
ever, this was a study of human cavernosal tissue from patients
undergoing gender-re-assignment, in which the men had received
long-term estrogen therapy (2e5 years). Whilst the effects of long
term estrogen therapy on erectile tissue are unknown, this therapy
has been shown to affect adrenoceptors elsewhere in body.19,20 In
addition, the study did not examine the two antagonists that are
able to discriminate between the a1A- and a1L-adrenoceptor iso-
forms, prazosin and RS17053,13,21,22 which we have previously used
to identify that a1L-adrenoceptors mediate contraction elsewhere
in the male lower urinary, speciﬁcally the human prostate23 and
vas deferens.24 A small clinical trial of a selective a1A-adrenoceptor
antagonist also failed to show any improvement in erectile
dysfunction,25 leading to speculation that the a1L-adrenoceptor may
be important functionally in human penile erectile tissue.
Thus, the aim of this studywas to determinewhether the a1A- or
the a1L-adrenoceptor subtype mediates contraction of human
erectile tissue.
2. Materials and methods
Erectile tissue was obtained as remnants of surgery from con-
senting patients undergoing urethroplasty (mean age ¼ 38.7 ± 5.4
years). All tissues were obtained with full informed consent and
with approval from the appropriate local ethics committee, South
Shefﬁeld Hospitals Ethics Committee (Shefﬁeld, UK), Greenslopes
Private Hospital Research and Ethics Committee and Bond Univer-
sity Human Research Ethics Committee (Queensland, Australia).
2.1. Functional experiments
Strips of erectile tissue (10  3  5 mm) were mounted in organ
baths at 37 C containing Krebs-bicarbonate solution (composition:
in mM: NaCl 118.4, KCl 4.7, CaCl2 1.9, NaHCO3 25.0, MgSO4 1.2,
KH2PO4 1.2 and glucose 11.7) and gassed with 5% CO2 in oxygen.
Tissues were set-up under a resting tension of 1.5 g and isometric
contractions recorded via UF1 transducers linked to a PC via a
Cambridge Electronic Design 1401 analogue to digital interface,
using LabChart software (ADInstruments).
Tissues were equilibrated for 60 min, with several
changes of bathing solution. Following equilibration cumulative
concentrationeresponse curves to noradrenaline were obtained in
the absence or presence of BMY7378, which is 30e100-fold selec-
tive for the a1D-adrenoceptor over the a1A-adrenoceptor26 and was
used at 100 nM to determine involvement of the a1D-adrenoceptor.
Cumulative concentrationeresponse curves to noradrenaline were
also obtained in the absence and presence of the a1A-, a1L- and a1D-
adrenoceptor antagonist tamsulosin (3 & 10 nM), the a1A-adreno-
ceptor antagonist 5-Methylurapidil (30 nM), the a1A-adrenoceptor
antagonist RS17053 (30& 300 nM) (discriminates between a1A and
a1L), and the a1A-, a1B- and a1D-adrenoceptor antagonist prazosin
(30e300 nM) (also discriminates between a1A and a1L). Tissues
were pre-incubated with antagonists for 60 min. Control experi-
ments (without the addition of antagonist) were performed in
parallel and used to correct for any time-dependent changes in
tissue sensitivity. Contractions to the a1A-adrenoceptor selective
agonist A61603 were also obtained. All experiments were per-
formed in the presence of cocaine (10 mM) and corticosterone(10 mM) to prevent amine uptake and propranolol (1 mM) and
yohimbine (0.5 mM) to antagonize b- and a2-adrenoceptors
respectively.
2.2. Radioligand binding experiments
For radioligand binding experiments tissues were homogenized
in 40 volumes (w/v) of ice cold Tris buffer (50 mM at pH 7.4) using
an Ultra-Turrax homogenizer for 30 s, followed by ﬁve strokes of a
glass-Teﬂon homogenizer. The homogenate was ﬁltered through
muslin, re-homogenized with ten strokes, and then centrifuged
twice at 45 000 g for 10 min. The ﬁnal pellet was resuspended in
Tris buffer for use in the binding assay.
Each binding assay was performed in duplicate using 100 ml of
membranes in a ﬁnal volume of 250 ml. Phentolamine was used to
displace the radioligand [3H]tamsulosin and determine non-
speciﬁc binding, at a concentration of 10 mM, since this is
100e1000-fold greater than its dissociation constant at the a1-
subtypes.27 Incubations were performed at 37 C for 30 min and
the reaction stopped by vacuum ﬁltration through glass-ﬁber ﬁlters
(Whatman GF/C) pre-soaked in 0.3% polyethylenimine. The ﬁlters
were washed twice with 5 ml of ice-cold Tris buffer and the
radioactivity remaining on the ﬁlters was determined using stan-
dard scintillation counting methods with Packard ‘Emulsiﬁer safe’
scintillation ﬂuid. In saturation binding experiments nine concen-
trations of [3H]tamsulosin (20pMe5 nM) were examined. Protein
content of the membrane solution was determined by the method
of Lowry et al., 1951, using bovine serum albumin (BSA) as stan-
dard.28 Competition binding was performed in duplicate using [3H]
tamsulosin (700 pM) and a range of concentrations of prazosin
(1 pMe500 nM).
2.3. Data analysis
Increases in developed tension in response to the agonists
were plotted as a percentage of the maximum increase for each
concentrationeresponse curve and expressed as mean ± SEM.
Individual EC50 values (concentration producing a half-maximal
response) were determined by non-linear regression of sigmoidal
doseeresponse curves (variable slope) using GraphPad Prism soft-
ware (La Jolla, CA, USA). Geometric mean EC50 values with 95%
conﬁdence limits were also calculated. Where several concentra-
tions of antagonist were examined, Schild plots were constructed
and slopes calculated for evidence of a competitive mechanism of
action. Apparent pKD values (log dissociation constant) were
determined from individual shifts of concentrationeresponse curves
using the equation:
pKD ¼ logðCR  1Þ  log½B
where CR is the concentration-ratio (ratio of the EC50 values in the
presence and absence of antagonist) obtained with a concentration
[B] of antagonist.29
Statistical signiﬁcancewas determined using a two-tailed paired
Student's t-test for log EC50 values, maximum responses and Hill
slopes, and using a two-tailed Student's t-test for Schild slopes.
GraphPad Prism software was also used to analyze the radio-
ligand binding data after correcting the free radioligand concen-
tration for any membrane bound radioligand. The density of
binding sites and radioligand afﬁnity were calculated using
non-linear curve ﬁtting, whilst competition data were ﬁtted to a
one- or two-site model, and the IC50 value converted to a KD
value.30 The suitability of a two-site ﬁt was assessed by an F-test.
A two-tailed unpaired Student's t-test was applied to assess
whether Hill slopes differed from unity.
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(±)-Noradrenaline, cocaine, (±)propranolol, yohimbine (all hy-
drochloride salts) and corticosterone 21-acetatewere obtained from
Sigma-Aldrich (Poole, UK). (-)-Tamsulosin hydrochloride (YM617)
was a gift from Yamanouchi Europe B.V. (Leiderdorp, Netherlands).
5-Methylurapidil, BMY7378 dihydrochloride and prazosin were
obtained from Research Biochemicals Inc (Natick, MA, USA).
RS17053 hydrochloride and A61603 hydrobromide were obtained
from Tocris Cookson Ltd (Bristol, UK). All other chemicals were of
reagent grade. Corticosteronewas dissolved in 70% ethanol. RS17053
was dissolved in 100% DMSO and diluted in 5 mM phosphoric acid.
Prazosinwas dissolved in distilledwater with a drop of glacial acetic
acid and diluted in distilled water. All other drugs were dissolved in
distilled water and diluted in Krebs solution. [3H]Tamsulosin
([phenoxy-3H]-YM617, speciﬁc activity 1117.4 Gbq mol1) was
obtained from NEN (Boston, MA). All reagents were Analar grade.
3. Results
3.1. Responses to agonists
Both noradrenaline and the a1A-adrenoceptor selective agonist
A61603 caused concentration-dependent contractions in isolated
strips of human erectile tissue (Fig. 1). A61603 was 21-fold more
potent than noradrenaline, having a signiﬁcantly lower (P < 0.05,
n¼ 8) geometric mean EC50 value of 0.13 (0.04e0.39) mMcompared
with 2.70 (1.47e4.96) mM for noradrenaline. A61603 acted as a full
agonist, eliciting a maximum contraction of 108.31 ± 19.40%
relative to noradrenaline (Fig. 1).
3.2. Effect of antagonists on noradrenaline contractions
5-Methylurapidil (30 nM) and tamsulosin (3 & 10 nM) caused
rightward shifts of noradrenaline concentrationeresponse curves
without affecting maximum contractions (Fig. 2A & B), although
the Hill slope for noradrenaline in the presence 10 nM tamsulosin
(0.78 ± 0.14) was signiﬁcantly lower (P < 0.05) than the Hill slope in
the absence of this antagonist (1.05 ± 0.06). Both 5-methyurapidil
and tamsulosin had relatively high afﬁnities for the a1-adreno-
ceptors in human erectile tissue, with apparent pKD values of
8.1 ± 0.20 (n ¼ 5) and 9.7 ± 0.3 (n ¼ 8) respectively.
In contrast, the a1D-adrenoceptor selective antagonist BMY7378
at a concentration of 100 nM failed to signiﬁcantly affect
noradrenaline concentrationeresponse curves (shift ¼ 1.18 ± 0.46,
n¼ 5) (Fig. 2C). The a1A-adrenoceptor selective antagonist RS17053
(low afﬁnity for the a1L-adrenoceptor), at 30 nM, also failed to shiftFig. 1. Mean concentrationeresponse curves of human erectile tissue to noradrenaline
and A61603. Responses are plotted as a percentage of the maximum response to
noradrenaline (n ¼ 8). All experiments were performed in the presence of cocaine
(10 mM), corticosterone (10 mM), propranolol (1 mM) and yohimbine (0.5 mM) to inhibit
amine uptake, b-adrenoceptors and a2-adrenoceptors, respectively.noradrenaline concentrationeresponse curves (Fig. 2D), although
at a higher concentration of 300 nM it did shift noradrenaline
curves to the right, with a signiﬁcant increase in noradrenaline EC50
values (P < 0.05) and yielding an apparent pKD value of 6.9 ± 0.2
(n ¼ 5). The antagonism appeared to be competitive since
maximum responses to noradrenaline were not depressed and the
Hill slopes in the presence of RS17053 were not signiﬁcantly
different from those in the absence of antagonist.
Prazosin (30e300 nM) produced concentration-related dextral
shifts of noradrenaline concentrationeresponse curves without any
change in maximum response or in the Hill slopes (Fig. 3), with a
mean pKD value of 8.2 ± 0.1 (n ¼ 14). Three concentrations of
prazosin were examined and the slope of the Schild plot was not
signiﬁcantly different from unity (slope 0.92 ± 0.21, P ¼ 0.71) and
had an intercept on the abscissa of 8.4 (Fig. 3).
3.3. Radioligand binding experiments
[3H]Tamsulosin bound to human erectile tissue membranes
with a high afﬁnity (mean pKD of 10.3 ± 0.1). The binding was
saturable, and the density of binding sites was 28.1 ± 1.4 fmol mg1
protein (Fig. 4). In a single competition experiment performed in
duplicate and using tissue pooled from 4 patients, prazosin
displaced [3H]tamsulosin from a single population of binding sites
with a relatively low afﬁnity for prazosin (pKi of 8.9, Fig. 4).
4. Discussion
The role of adrenoceptors in human penile erection is still not
fully understood. While stimulation of postsynaptic a1-adreno-
ceptors is known to mediate contraction of the erectile smooth
muscle, leading to ﬂaccidity and detumescence,1 there is still con-
troversy regarding the predominant a1-adrenoceptor subtype
mediating this contraction in humans. In the present studywe used
a range of subtype selective agonists and antagonists to determine
whether the a1L-adrenoceptor subtype is predominant in human
erectile tissue, as we have shownpreviously for the human prostate
and vas deferens.23,24
A61603, an agonist that is highly selective for a1A-adreno-
ceptors,31 was 21-fold more potent in causing contraction of erec-
tile tissue than the endogenous agonist noradrenaline. This value is
comparable to the values we have obtained previously for human
prostate, under identical conditions, where A61603was found to be
13-times more potent than noradrenaline (Chess-Williams,
unpublished observations). Thus, the agonist data suggest the
presence of the a1A-adrenoceptor subtype in human erectile tissue.
Tamsulosin is a competitive antagonist with a very high afﬁnity
(>10) at a1A- and a1D-adrenoceptors.32 Both concentrations of
tamsulosin used in this study (3 and 10 nM) caused rightward shifts
of the noradrenaline concentrationeresponse curves and the high
mean afﬁnity estimate (apparent pKD of 9.7) is consistent with the
involvement of a1A and/or a1D-adrenoceptors, and not a1B-adreno-
ceptors. At 3 nM tamsulosin did not affect the Hill slope for
noradrenaline, and (presumably the more accurate) afﬁnity esti-
mate was even higher, at 9.9, and identical to that we showed at
the a1A/L-adrenoceptors of the human prostate.32 At the higher
concentration (10 nM) tamsulosin reduced the Hill slope for
noradrenaline. This is not surprising since tamsulosin has been re-
ported to signiﬁcantly affect maximum contractions (i.e. have an
unsurmountable action) in a number of smooth muscle prepara-
tions, including in our previous studies of human prostate27 and
human vas deferens.33 The fact that tamsulosin is a competitive
antagonist with a very high afﬁnity (>10) at a1A- and a1D-adreno-
ceptors,32 and may bind irreversibly to these receptors, may explain
this unsurmountable action.
Fig. 2. Mean concentrationeresponse curves of human erectile tissue to noradrenaline in the absence and presence of (A) 5-methylurapidil (5-MU) (n ¼ 5), (B) tamsulosin
(n ¼ 3e5), (C) BMY7378 (n ¼ 5), and (D) RS17053 (n ¼ 4e6).
B.J. Davis et al. / Journal of Pharmacological Sciences 137 (2018) 366e371 369The involvement of a1A- or a1D-adrenoceptors was further
supported by the relatively high afﬁnity estimate (pKD 8.1) obtained
for the antagonist 5-methylurapidil. This antagonist has a lower
afﬁnity at a1B-adrenoceptors (pKD ¼ 7.2),34 and thus the afﬁnity
estimate obtained in the present study is higher than would be
expected if a1B-adrenoceptors were mediating the contractions to
noradrenaline in the human erectile tissue. An afﬁnity of 7.8 has
been reported for 5-methylurapidil at a1D-adrenoceptors.34 To rule
out the involvement of a1D-adrenoceptors, experiments were per-
formed in the presence of BMY7378, which has a high afﬁnity for
a1D-adrenoceptors (pKi 8.2)26 and is 100-fold selective for this
subtype over the a1B- and a1A-receptor subtypes. If the a1D-receptor
was involved in contractions, the concentration of BMY7378 used
(100 nM) should have produced at least a 10-fold shift. The lack of
shift of the noradrenaline concentrationeresponse curves, and the
lack of effect on the Hill slopes, indicates that a1D-adrenoceptors are
not involved in smooth muscle contraction in this tissue.
These results indicate that responses of human erectile tissue are
mediated via a1A-adrenoceptors. However, a1A-adrenoceptors can
exist as the distinct functional phenotype a1L-adrenoceptor, and
many a1A-selective antagonists, including tamsulosin and
5-methylurapidil, have a high afﬁnity for a1L-adrenoceptors in
addition to a1A-adrenoceptors. Prazosin and RS17053 are two an-
tagonists that can distinguish between a1A- and a1L-adrenoceptors.
Prazosin has a high afﬁnity at all cloned a1-adrenoceptors
(pKD > 9.5), but a low afﬁnity (pKD < 9) at the a1L-adrenoceptor.13,21In the present study the afﬁnity estimate for prazosin in human
erectile tissue (pKD value of 8.2) was low, too low to indicate an
action at one of the cloned a1-adrenoceptors, and instead suggesting
the involvement of a1L-adrenoceptors. Three concentrations of
prazosin were examined (30e300 nM) and the resulting Schild plot
had a slope that was not signiﬁcantly different to unity. Further-
more, even the highest concentration of prazosin did not affect the
maximum response or Hill slope obtained to noradrenaline. Thus,
prazosin appeared to be acting at a single receptor population, as a
purely competitive antagonist, with a low afﬁnity for the a1-adre-
noceptor of human erectile tissue (i.e. a1L).
This is supported by the effects of RS17053, which has a high
afﬁnity at cloned and native a1A-adrenoceptors (pKD ¼ 9.1e9.9), but
a low afﬁnity at the a1L-adrenoceptor (pKD ¼ 7.3).22 At a concen-
tration of 30 nM, RS17053 failed to signiﬁcantly affect responses to
noradrenaline, and only at the higher concentration of 300 nM did it
cause a small dextral shift of noradrenaline concentrationeresponse
curves, yielding a low afﬁnity estimate of 6.9, similar to that previ-
ously reported at the a1L-adrenoceptor.
The a1L-adrenoceptor has been shown to originate from the
a1A-adrenoceptor gene,35,36 but is functionally and pharmacologi-
cally unique compared to the classical a1-adrenoceptor subtypes.
a1L-adrenoceptor pharmacology can be induced in cells expressing
the a1A-adrenoceptor subtype bymanipulation of the experimental
conditions, and it is possible that the a1L-adrenoceptor represents
an alternative afﬁnity state of the a1A-adrenoceptor.14 The proposed
Fig. 3. (A) Mean concentrationeresponse curves of human erectile tissue to
noradrenaline in the absence and presence of prazosin (30e300 nM, n ¼ 4e5). (B)
Schild plot for the antagonism of responses to noradrenaline by prazosin.
Fig. 4. (A) Representative saturation curve and (B) Scatchard plot for [3H]tamsulosin
binding to membranes prepared from human erectile tissue. Experiments were
performed in duplicate with tissues from 4 patients. (C) Competition binding curve for
prazosin displacement of [3H]tamsulosin binding.
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remain controversial, but may involve receptor-interacting
proteins.37 In cell lines expressing a1A-adrenoceptors, the a1A-
adrenoceptor phenotype was shown to be downregulated by the
presence of CRELD1a, a cysteine-rich epidermal growth factor-like
protein, which interacts with the a1A-adrenoceptor to alter binding
proﬁle.38 a1A-adrenoceptors have also been shown to form speciﬁc
receptor heteromers with chemokine-receptors, which changes
their pharmacological proﬁle.39
Since interacting proteins such as CRELD1a would be expected
to be removed during the normal homogenization of tissues for
radioligand binding experiments, it has been proposed that in order
to detect the a1L-adrenoceptor phenotype via radioligand binding
assays, whole cells or intact tissues segments must be used,40 and
that the a1L-adrenoceptor phenotype is not demonstrable at the
protein level using such a technique. However, this was not the case
in the present study. Using [3H]tamsulosin, a radioligand with high
afﬁnity for the a1L-adrenoceptor, we found that radioligand binding
data supported our functional observations. [3H]tamsulosin bound
to erectile tissue with high afﬁnity (>10), as we have shown pre-
viously at the a1L-adrenoceptor of the human prostate.23 Whereas
in the human prostate we identiﬁed two binding sites for prazosin,
the high afﬁnity site (a1A) with an afﬁnity (pKi) of 10.3 and the low
afﬁnity site (a1L) with an afﬁnity (pKi) of 8.9, in the present study in
erectile tissue a single binding site was identiﬁed by prazosin, with
an afﬁnity (pKi) of 8.9. This is identical to that of the low afﬁnity site
identiﬁed for prazosin in the human prostate using this radioligand
and suggests a homogeneous population of a1L-adrenoceptors in
human erectile tissue.In conclusion, this study demonstrates the a1L-adrenoceptor
subtype at both the functional and protein level in human erectile
tissue and conﬁrms that erectile smooth muscle contraction is
mediated via the a1L-adrenoceptor. The a1L-adrenoceptor is also
found in the human prostate and is the target of current a1A/L-
adrenoceptor antagonists used to treat benign prostatic hyperpla-
sia, and so this may explain the improvement in sexual function
reported in patients receiving these agents. Since the a1L-adreno-
ceptor is also predominant in the human vas deferens, any future
drug development aimed at targeting a1L-adrenoceptors for
erectile dysfunction would need to consider the potential for ane-
jaculatory effects, which vary between the current a1A-adreno-
ceptor antagonists and may or may not be mediated via
a1-adrenoceptors.11
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